{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["DFT", "EGFR", "MD simulations", "Molecular docking", "anticancer", "semi-synthesis", "theobromine derivative"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36144596", "DateCompleted": {"Year": "2022", "Month": "09", "Day": "26"}, "DateRevised": {"Year": "2022", "Month": "09", "Day": "28"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "09", "Day": "09"}], "Language": ["eng"], "ELocationID": ["5859", "10.3390/molecules27185859"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "27", "Issue": "18", "PubDate": {"Year": "2022", "Month": "Sep", "Day": "09"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "New Anticancer Theobromine Derivative Targeting EGFR<sup>WT</sup> and EGFR<sup>T790M</sup>: Design, Semi-Synthesis, In Silico, and In Vitro Anticancer Studies.", "Abstract": {"AbstractText": ["Based on the pharmacophoric features of EGFR inhibitors, a new semisynthetic theobromine-derived compound was designed to interact with the catalytic pocket of EGFR. Molecular docking against wild (EGFR<sup>WT</sup>; PDB: 4HJO) and mutant (EGFR<sup>T790M</sup>; PDB: 3W2O) types of EGFR-TK indicated that the designed theobromine derivative had the potential to bind to that pocket as an antiangiogenic inhibitor. The MD and MM-GBSA experiments identified the exact binding with optimum energy and dynamics. Additionally, the DFT calculations studied electrostatic potential, stability, and total electron density of the designed theobromine derivative. Both in silico ADMET and toxicity analyses demonstrated its general likeness and safety. We synthesized the designed theobromine derivative (compound <b>XI</b>) which showed an IC<sub>50</sub> value of 17.23 nM for EGFR inhibition besides IC<sub>50</sub> values of 21.99 and 22.02 \u00b5M for its cytotoxicity against A549 and HCT-116 cell lines, respectively. Interestingly, compound <b>XI</b> expressed a weak cytotoxic potential against the healthy W138 cell line (IC<sub>50</sub> = 49.44 \u00b5M, 1.6 times safer than erlotinib), exhibiting the high selectivity index of 2.2. Compound <b>XI</b> arrested the growth of A549 at the G2/M stage and increased the incidence of apoptosis."]}, "AuthorList": [{"Identifier": ["0000-0002-2546-8035"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh 13713, Saudi Arabia."}], "LastName": "Elkaeed", "ForeName": "Eslam B", "Initials": "EB"}, {"Identifier": ["0000-0003-3709-1930"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Yousef", "ForeName": "Reda G", "Initials": "RG"}, {"Identifier": ["0000-0003-0893-6703"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Elkady", "ForeName": "Hazem", "Initials": "H"}, {"Identifier": ["0000-0003-4497-5013"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia."}], "LastName": "Alsfouk", "ForeName": "Aisha A", "Initials": "AA"}, {"Identifier": ["0000-0001-7552-0914"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemistry Department, Faculty of Science, New Valley University, El-Kharja 72511, Egypt."}], "LastName": "Husein", "ForeName": "Dalal Z", "Initials": "DZ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biophysics Department, Faculty of Science, Cairo University, Cairo 12613, Egypt."}], "LastName": "Ibrahim", "ForeName": "Ibrahim M", "Initials": "IM"}, {"Identifier": ["0000-0001-8566-1980"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}, {"Identifier": [], "Affiliation": "Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria 21934, Egypt."}], "LastName": "Metwaly", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": ["0000-0002-6955-2263"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Eissa", "ForeName": "Ibrahim H", "Initials": "IH"}], "GrantList": [{"GrantID": "PNURSP2022R116", "Agency": "Princess Nourah bint Abdulrahman University", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "DA87705X9K", "NameOfSubstance": "Erlotinib Hydrochloride"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "EGFR protein, human"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ErbB Receptors"}, {"RegistryNumber": "OBD445WZ5P", "NameOfSubstance": "Theobromine"}], "MeshHeadingList": [{"QualifierName": ["chemistry"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "ErbB Receptors"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Erlotinib Hydrochloride"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Lung Neoplasms"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": [], "DescriptorName": "Mutation"}, {"QualifierName": ["chemistry"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Theobromine"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Abd El-Mageed M.M., Eissa A.A., Farag A.E.-S., Osman E.E.A. Design and synthesis of novel furan, furo [2, 3-d] pyrimidine and furo [3, 2-e][1,2,4] triazolo [1, 5-c] pyrimidine derivatives as potential VEGFR-2 inhibitors. Bioorganic Chem. 2021;116:105336. doi: 10.1016/j.bioorg.2021.105336.", "ArticleIdList": ["10.1016/j.bioorg.2021.105336", "34530235"]}, {"Citation": "Chaudhari P., Bari S., Surana S., Shirkhedkar A., Wakode S., Shelar S., Racharla S., Ugale V., Ghodke M. Logical synthetic strategies and structure-activity relationship of indolin-2-one hybrids as small molecule anticancer agents: An Overview. J. Mol. Struct. 2021;1247:131280. doi: 10.1016/j.molstruc.2021.131280.", "ArticleIdList": ["10.1016/j.molstruc.2021.131280"]}, {"Citation": "El-Dash Y., Elzayat E., Abdou A.M., Hassan R.A. Novel thienopyrimidine-aminothiazole hybrids: Design, synthesis, antimicrobial screening, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and VEGFR-2 inhibition. Bioorganic Chem. 2021;114:105137. doi: 10.1016/j.bioorg.2021.105137.", "ArticleIdList": ["10.1016/j.bioorg.2021.105137", "34237644"]}, {"Citation": "Nicholson R.I., Gee J.M.W., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer. 2001;37:9\u201315. doi: 10.1016/S0959-8049(01)00231-3.", "ArticleIdList": ["10.1016/S0959-8049(01)00231-3", "11597399"]}, {"Citation": "Spano J.-P., Lagorce C., Atlan D., Milano G., Domont J., Benamouzig R., Attar A., Benichou J., Martin A., Morere J.-F. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann. Oncol. 2005;16:102\u2013108. doi: 10.1093/annonc/mdi006.", "ArticleIdList": ["10.1093/annonc/mdi006", "15598946"]}, {"Citation": "Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R., Carotenuto A., De Feo G., Caponigro F., Salomon D.S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366:2\u201316. doi: 10.1016/j.gene.2005.10.018.", "ArticleIdList": ["10.1016/j.gene.2005.10.018", "16377102"]}, {"Citation": "Ayati A., Moghimi S., Salarinejad S., Safavi M., Pouramiri B., Foroumadi A. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorganic Chem. 2020;99:103811. doi: 10.1016/j.bioorg.2020.103811.", "ArticleIdList": ["10.1016/j.bioorg.2020.103811", "32278207"]}, {"Citation": "Metwaly A.M., Ghoneim M.M., Eissa I.H., Elsehemy I.A., Mostafa A.E., Hegazy M.M., Afifi W.M., Dou D. Traditional ancient Egyptian medicine: A review. Saudi J. Biol. Sci. 2021;28:5823\u20135832. doi: 10.1016/j.sjbs.2021.06.044.", "ArticleIdList": ["10.1016/j.sjbs.2021.06.044", "PMC8459052", "34588897"]}, {"Citation": "Han X., Yang Y., Metwaly A.M., Xue Y., Shi Y., Dou D. The Chinese herbal formulae (Yitangkang) exerts an antidiabetic effect through the regulation of substance metabolism and energy metabolism in type 2 diabetic rats. J. Ethnopharmacol. 2019;239:111942. doi: 10.1016/j.jep.2019.111942.", "ArticleIdList": ["10.1016/j.jep.2019.111942", "31075380"]}, {"Citation": "Newman D.J., Cragg G.M. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 2016;79:629\u2013661. doi: 10.1021/acs.jnatprod.5b01055.", "ArticleIdList": ["10.1021/acs.jnatprod.5b01055", "26852623"]}, {"Citation": "Barcz E., Sommer E., Janik P., Marianowski L., Skopinska-Rozewska E. Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells. Oncol. Rep. 2000;7:1285\u20131376. doi: 10.3892/or.7.6.1285.", "ArticleIdList": ["10.3892/or.7.6.1285", "11032931"]}, {"Citation": "Kakuyamanee Iwazaki A., Sadzuka Y. Effect of methylxanthine derivatives on doxorubicin transport and antitumor activity. Curr. Drug Metab. 2001;2:379\u2013395. doi: 10.2174/1389200013338270.", "ArticleIdList": ["10.2174/1389200013338270", "11766989"]}, {"Citation": "Sultani H.N., Ghazal R.A., Hayallah A.M., Abdulrahman L.K., Abu-Hammour K., AbuHammad S., Taha M.O., Zihlif M.A. Inhibitory effects of new mercapto xanthine derivatives in human mcf7 and k562 cancer cell lines. J. Heterocycl. Chem. 2017;54:450\u2013456. doi: 10.1002/jhet.2602.", "ArticleIdList": ["10.1002/jhet.2602"]}, {"Citation": "Woskresensky A. Ueber das Theobromin. Justus Liebigs Ann. Der Chem. 1842;41:125\u2013127. doi: 10.1002/jlac.18420410117.", "ArticleIdList": ["10.1002/jlac.18420410117"]}, {"Citation": "Smit H.J. Theobromine and the pharmacology of cocoa. Methylxanthines. 2011;200:201\u2013234.", "ArticleIdList": ["20859797"]}, {"Citation": "Fischer E. Untersuchungen in der Puringruppe. Springer; Berlin/Heidelberg, Germany: 1907. Synthese des Theobromins; pp. 265\u2013272."}, {"Citation": "Carla Cadon\u00e1 F., Kolinski Machado A., Farina Azzolin V., Barbisan F., Bortoluzzi Dornelles E., Glanzner W., Bayard Gon\u00e7alves P.D., Elias Assmann C., Esteves Ribeiro E., Beatrice M\u00e2nica da Cruz I. Guaran\u00e1 a caffeine-rich food increases oxaliplatin sensitivity of colorectal HT-29 cells by apoptosis pathway modulation. Anti-Cancer Agents Med. Chem. (Former. Curr. Med. Chem.-Anti-Cancer Agents) 2016;16:1055\u20131065. doi: 10.2174/1871520616666151217121138.", "ArticleIdList": ["10.2174/1871520616666151217121138", "26673759"]}, {"Citation": "Shojaei-Zarghani S., Khosroushahi A.Y., Rafraf M. Oncopreventive effects of theanine and theobromine on dimethylhydrazine-induced colon cancer model. Biomed. Pharmacother. 2021;134:111140. doi: 10.1016/j.biopha.2020.111140.", "ArticleIdList": ["10.1016/j.biopha.2020.111140", "33360052"]}, {"Citation": "Lee H.J., Lee K.W., Kang K.S., Kim D.Y., Park H.H., Lee M.J., Kim H.S., Kwon I.B. Theobromine with an Anti-Carcinogenic Activity. EP1304046A1. European Patent. 2001 October 18;"}, {"Citation": "Sugimoto N., Miwa S., Hitomi Y., Nakamura H., Tsuchiya H., Yachie A. Theobromine, the primary methylxanthine found in Theobroma cacao, prevents malignant glioblastoma proliferation by negatively regulating phosphodiesterase-4, extracellular signal-regulated kinase, Akt/mammalian target of rapamycin kinase, and nuclear factor-kappa B. Nutr. Cancer. 2014;66:419\u2013423.", "ArticleIdList": ["24547961"]}, {"Citation": "Gil M., Skopi\u0144ska-R\u00f3zewska E., Radomska D., Demkow U., Skurzak H., Rochowska M., Beuth J., Roszkowski K. Effect of purinergic receptor antagonists suramin and theobromine on tumor-induced angiogenesis in BALB/c mice. Folia Biol. 1993;39:63\u201368.", "ArticleIdList": ["7504997"]}, {"Citation": "Barcz E., Sommer E., Sokolnicka I., Gawrychowski K., Roszkowska-Purska K., Janik P., Skopinska-R\u00f3zewska E. The influence of theobromine on angiogenic activity and proangiogenic cytokines production of human ovarian cancer cells. Oncol. Rep. 1998;5:517\u2013537. doi: 10.3892/or.5.2.517.", "ArticleIdList": ["10.3892/or.5.2.517", "9468592"]}, {"Citation": "da Rosa R., Schenkel E.P., Bernardes L.S.C. Semisynthetic and newly designed derivatives based on natural chemical scaffolds: Moving beyond natural products to fight Trypanosoma cruzi. Phytochem. Rev. 2020;19:105\u2013122. doi: 10.1007/s11101-020-09659-8.", "ArticleIdList": ["10.1007/s11101-020-09659-8"]}, {"Citation": "Goh G.B., Hodas N.O., Vishnu A. Deep learning for computational chemistry. J. Comput. Chem. 2017;38:1291\u20131307. doi: 10.1002/jcc.24764.", "ArticleIdList": ["10.1002/jcc.24764", "28272810"]}, {"Citation": "Eissa I.H., Alesawy M.S., Saleh A.M., Elkaeed E.B., Alsfouk B.A., El-Attar A.-A.M., Metwaly A.M. Ligand and Structure-Based In Silico Determination of the Most Promising SARS-CoV-2 nsp16-nsp10 2\u2032-o-Methyltransferase Complex Inhibitors among 3009 FDA Approved Drugs. Molecules. 2022;27:2287. doi: 10.3390/molecules27072287.", "ArticleIdList": ["10.3390/molecules27072287", "PMC9000629", "35408684"]}, {"Citation": "Elkady H., Elwan A., El-Mahdy H.A., Doghish A.S., Ismail A., Taghour M.S., Elkaeed E.B., Eissa I.H., Dahab M.A., Mahdy H.A. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. J. Enzym. Inhib. Med. Chem. 2022;37:397\u2013410. doi: 10.1080/14756366.2021.2015343.", "ArticleIdList": ["10.1080/14756366.2021.2015343", "PMC8725875", "34961427"]}, {"Citation": "Elkaeed E.B., Yousef R.G., Elkady H., Gobaara I.M.M., Alsfouk A.A., Husein D.Z., Ibrahim I.M., Metwaly A.M., Eissa I.H. The Assessment of Anticancer and VEGFR-2 Inhibitory Activities of a New 1H-Indole Derivative: In Silico and In Vitro Approaches. Processes. 2022;10:1391. doi: 10.3390/pr10071391.", "ArticleIdList": ["10.3390/pr10071391"]}, {"Citation": "Mohammed S.O., El Ashry E.S.H., Khalid A., Amer M.R., Metwaly A.M., Eissa I.H., Elkaeed E.B., Elshobaky A., Hafez E.E. Expression, Purification, and Comparative Inhibition of Helicobacter pylori Urease by Regio-Selectively Alkylated Benzimidazole 2-Thione Derivatives. Molecules. 2022;27:865. doi: 10.3390/molecules27030865.", "ArticleIdList": ["10.3390/molecules27030865", "PMC8838460", "35164122"]}, {"Citation": "Alanazi M.M., Elkady H., Alsaif N.A., Obaidullah A.J., Alkahtani H.M., Alanazi M.M., Alharbi M.A., Eissa I.H., Dahab M.A. New quinoxaline-based VEGFR-2 inhibitors: Design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies. RSC Adv. 2021;11:30315\u201330328. doi: 10.1039/D1RA05925D.", "ArticleIdList": ["10.1039/D1RA05925D", "PMC9044819", "35493991"]}, {"Citation": "Suleimen Y.M., Jose R.A., Suleimen R.N., Arenz C., Ishmuratova M.Y., Toppet S., Dehaen W., Alsfouk B.A., Elkaeed E.B., Eissa I.H. Jusanin, a New Flavonoid from Artemisia commutata with an In Silico Inhibitory Potential against the SARS-CoV-2 Main Protease. Molecules. 2022;27:1636. doi: 10.3390/molecules27051636.", "ArticleIdList": ["10.3390/molecules27051636", "PMC8911936", "35268738"]}, {"Citation": "Alanazi M.M., Elkady H., Alsaif N.A., Obaidullah A.J., Alanazi W.A., Al-Hossaini A.M., Alharbi M.A., Eissa I.H., Dahab M.A. Discovery of new quinoxaline-based derivatives as anticancer agents and potent VEGFR-2 inhibitors: Design, synthesis, and in silico study. J. Mol. Struct. 2021;1253:132220. doi: 10.1016/j.molstruc.2021.132220.", "ArticleIdList": ["10.1016/j.molstruc.2021.132220"]}, {"Citation": "Suleimen Y.M., Jose R.A., Suleimen R.N., Ishmuratova M.Y., Toppet S., Dehaen W., Alsfouk A.A., Elkaeed E.B., Eissa I.H., Metwaly A.M. Isolation and In Silico SARS-CoV-2 Main Protease Inhibition Potential of Jusan Coumarin, a New Dicoumarin from Artemisia glauca. Molecules. 2022;27:2281. doi: 10.3390/molecules27072281.", "ArticleIdList": ["10.3390/molecules27072281", "PMC9000794", "35408682"]}, {"Citation": "Eissa I.H., Khalifa M.M., Elkaeed E.B., Hafez E.E., Alsfouk A.A., Metwaly A.M. In Silico Exploration of Potential Natural Inhibitors against SARS-CoV-2 nsp10. Molecules. 2021;26:6151. doi: 10.3390/molecules26206151.", "ArticleIdList": ["10.3390/molecules26206151", "PMC8539059", "34684735"]}, {"Citation": "Elkaeed E.B., Elkady H., Belal A., Alsfouk B.A., Ibrahim T.H., Abdelmoaty M., Arafa R.K., Metwaly A.M., Eissa I.H. Multi-Phase In Silico Discovery of Potential SARS-CoV-2 RNA-Dependent RNA Polymerase Inhibitors among 3009 Clinical and FDA-Approved Related Drugs. Processes. 2022;10:530. doi: 10.3390/pr10030530.", "ArticleIdList": ["10.3390/pr10030530"]}, {"Citation": "Suleimen Y.M., Jose R.A., Suleimen R.N., Arenz C., Ishmuratova M., Toppet S., Dehaen W., Alsfouk A.A., Elkaeed E.B., Eissa I.H. Isolation and In Silico Anti-SARS-CoV-2 Papain-Like Protease Potentialities of Two Rare 2-Phenoxychromone Derivatives from Artemisia spp. Molecules. 2022;27:1216. doi: 10.3390/molecules27041216.", "ArticleIdList": ["10.3390/molecules27041216", "PMC8879996", "35209006"]}, {"Citation": "Alesawy M.S., Elkaeed E.B., Alsfouk A.A., Metwaly A.M., Eissa I.H. In silico screening of semi-synthesized compounds as potential inhibitors for SARS-CoV-2 papain-like protease: Pharmacophoric features, molecular docking, ADMET, toxicity and DFT studies. Molecules. 2021;26:6593. doi: 10.3390/molecules26216593.", "ArticleIdList": ["10.3390/molecules26216593", "PMC8588135", "34771004"]}, {"Citation": "Bonomi P. Erlotinib: A new therapeutic approach for non-small cell lung cancer. Expert Opin. Investig. Drugs. 2003;12:1395\u20131401. doi: 10.1517/13543784.12.8.1395.", "ArticleIdList": ["10.1517/13543784.12.8.1395", "12882624"]}, {"Citation": "Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73. doi: 10.1371/journal.pmed.0020073.", "ArticleIdList": ["10.1371/journal.pmed.0020073", "PMC549606", "15737014"]}, {"Citation": "Muhsin M., Graham J., Kirkpatrick P. Fresh from the pipeline: Gefitinib. Nat. Rev. Cancer. 2003;3:556\u2013557. doi: 10.1038/nrc1159.", "ArticleIdList": ["10.1038/nrc1159"]}, {"Citation": "Singh H., Walker A.J., Amiri-Kordestani L., Cheng J., Tang S., Balcazar P., Barnett-Ringgold K., Palmby T.R., Cao X., Zheng N. US Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast CancerFDA Approval Summary: Neratinib. Clin. Cancer Res. 2018;24:3486\u20133491. doi: 10.1158/1078-0432.CCR-17-3628.", "ArticleIdList": ["10.1158/1078-0432.CCR-17-3628", "29523624"]}, {"Citation": "Sequist L.V., Besse B., Lynch T.J., Miller V.A., Wong K.K., Gitlitz B., Eaton K., Zacharchuk C., Freyman A., Powell C. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non\u2013small-cell lung cancer. J. Clin. Oncol. 2010;28:3076\u20133083. doi: 10.1200/JCO.2009.27.9414.", "ArticleIdList": ["10.1200/JCO.2009.27.9414", "20479403"]}, {"Citation": "Kim Y., Ko J., Cui Z., Abolhoda A., Ahn J.S., Ou S.-H., Ahn M.-J., Park K. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol. Cancer Ther. 2012;11:784\u2013791. doi: 10.1158/1535-7163.MCT-11-0750.", "ArticleIdList": ["10.1158/1535-7163.MCT-11-0750", "22228822"]}, {"Citation": "Carroll J. Following Lethal Tox Report, Boehringer Scraps Plans for High-Speed Development, Kills $730M Hanmi Deal.  [(accessed on 20 May 2019)].  Available online:  https://endpts.com/following-lethal-tox-report-boehringer-scraps-plans-for-high-speed-development-kills-730m-hanmi-deal/"}, {"Citation": "Traxler P., Bold G., Frei J., Lang M., Lydon N., Mett H., Buchdunger E., Meyer T., Mueller M., Furet P. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino) pyrazolo [3, 4-d] pyrimidines. J. Med. Chem. 1997;40:3601\u20133616. doi: 10.1021/jm970124v.", "ArticleIdList": ["10.1021/jm970124v", "9357527"]}, {"Citation": "Ducray R., Ballard P., Barlaam B.C., Hickinson M.D., Kettle J.G., Ogilvie D.J., Trigwell C.B. Novel 3-alkoxy-1H-pyrazolo [3, 4-d] pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors. Bioorganic Med. Chem. Lett. 2008;18:959\u2013962. doi: 10.1016/j.bmcl.2007.12.035.", "ArticleIdList": ["10.1016/j.bmcl.2007.12.035", "18182285"]}, {"Citation": "Gaber A.A., Bayoumi A.H., El-Morsy A.M., Sherbiny F.F., Mehany A.B., Eissa I.H. Design, synthesis and anticancer evaluation of 1H-pyrazolo [3, 4-d] pyrimidine derivatives as potent EGFRWT and EGFRT790M inhibitors and apoptosis inducers. Bioorganic Chem. 2018;80:375\u2013395. doi: 10.1016/j.bioorg.2018.06.017.", "ArticleIdList": ["10.1016/j.bioorg.2018.06.017", "29986185"]}, {"Citation": "Gandin V., Ferrarese A., Dalla Via M., Marzano C., Chilin A., Marzaro G. Targeting kinases with anilinopyrimidines: Discovery of N-phenyl-N\u2019-[4-(pyrimidin-4-ylamino) phenyl] urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. Sci. Rep. 2015;5:16750. doi: 10.1038/srep16750.", "ArticleIdList": ["10.1038/srep16750", "PMC4645160", "26568452"]}, {"Citation": "Traxler P., Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. 1999;82:195\u2013206. doi: 10.1016/S0163-7258(98)00044-8.", "ArticleIdList": ["10.1016/S0163-7258(98)00044-8", "10454197"]}, {"Citation": "Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer. 2009;9:28. doi: 10.1038/nrc2559.", "ArticleIdList": ["10.1038/nrc2559", "19104514"]}, {"Citation": "Eldehna W.M., El Hassab M.A., Elsayed Z.M., Al-Warhi T., Elkady H., Abo-Ashour M.F., Abourehab M.A.S., Eissa I.H., Abdel-Aziz H.A. Design, synthesis, in vitro biological assessment and molecular modeling insights for novel 3-(naphthalen-1-yl)-4,5-dihydropyrazoles as anticancer agents with potential EGFR inhibitory activity. Sci. Rep. 2022;12:12821. doi: 10.1038/s41598-022-15050-8.", "ArticleIdList": ["10.1038/s41598-022-15050-8", "PMC9329325", "35896557"]}, {"Citation": "Mowafy S., Galanis A., Doctor Z.M., Paranal R.M., Lasheen D.S., Farag N.A., J\u00e4nne P.A., Abouzid K.A. Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives. Biorg. Med. Chem. 2016;24:3501\u20133512. doi: 10.1016/j.bmc.2016.05.063.", "ArticleIdList": ["10.1016/j.bmc.2016.05.063", "27288180"]}, {"Citation": "Zhao Z., Wu H., Wang L., Liu Y., Knapp S., Liu Q., Gray N.S. Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS Chem. Biol. 2014;9:1230\u20131241. doi: 10.1021/cb500129t.", "ArticleIdList": ["10.1021/cb500129t", "PMC4068218", "24730530"]}, {"Citation": "Furet P., Caravatti G., Lydon N., Priestle J.P., Sowadski J.M., Trinks U., Traxler P. Modelling study of protein kinase inhibitors: Binding mode of staurosporine and origin of the selectivity of CGP 52411. J. Comput.-Aided Mol. Des. 1995;9:465\u2013472. doi: 10.1007/BF00124317.", "ArticleIdList": ["10.1007/BF00124317", "8789188"]}, {"Citation": "Liu Y., Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006;2:358\u2013364. doi: 10.1038/nchembio799.", "ArticleIdList": ["10.1038/nchembio799", "16783341"]}, {"Citation": "Nasser A.A., Eissa I.H., Oun M.R., El-Zahabi M.A., Taghour M.S., Belal A., Saleh A.M., Mehany A.B., Luesch H., Mostafa A.E. Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR WT and EGFR T790M. Org. Biomol. Chem. 2020;18:7608\u20137634. doi: 10.1039/D0OB01557A.", "ArticleIdList": ["10.1039/D0OB01557A", "32959865"]}, {"Citation": "Elzahabi H.S., Nossier E.S., Alasfoury R.A., El-Manawaty M., Sayed S.M., Elkaeed E.B., Metwaly A.M., Hagras M., Eissa I.H. Design, synthesis, and anti-cancer evaluation of new pyrido [2, 3-d] pyrimidin-4 (3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers. J. Enzym. Inhib. Med. Chem. 2022;37:1053\u20131076. doi: 10.1080/14756366.2022.2062752.", "ArticleIdList": ["10.1080/14756366.2022.2062752", "PMC9291687", "35821615"]}, {"Citation": "Elmetwally S.A., Saied K.F., Eissa I.H., Elkaeed E.B. Design, synthesis and anticancer evaluation of thieno [2, 3-d] pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Bioorganic Chem. 2019;88:102944. doi: 10.1016/j.bioorg.2019.102944.", "ArticleIdList": ["10.1016/j.bioorg.2019.102944", "31051400"]}, {"Citation": "Belal A., Abdel Gawad N.M., Mehany A.B., Abourehab M.A., Elkady H., Al-Karmalawy A.A., Ismael A.S. Design, synthesis and molecular docking of new fused 1 H-pyrroles, pyrrolo [3, 2-d] pyrimidines and pyrrolo [3, 2-e][1,4] diazepine derivatives as potent EGFR/CDK2 inhibitors. J. Enzym. Inhib. Med. Chem. 2022;37:1884\u20131902. doi: 10.1080/14756366.2022.2096019.", "ArticleIdList": ["10.1080/14756366.2022.2096019", "PMC9272933", "35801486"]}, {"Citation": "Belal A., Elanany M.A., Santali E.Y., Al-Karmalawy A.A., Aboelez M.O., Amin A.H., Abdellattif M.H., Mehany A.B., Elkady H. Screening a Panel of Topical Ophthalmic Medications against MMP-2 and MMP-9 to Investigate Their Potential in Keratoconus Management. Molecules. 2022;27:3584. doi: 10.3390/molecules27113584.", "ArticleIdList": ["10.3390/molecules27113584", "PMC9182209", "35684529"]}, {"Citation": "Abdallah A.E., Alesawy M.S., Eissa S.I., El-Fakharany E.M., Kalaba M.H., Sharaf M.H., Shama N.M.A., Mahmoud S.H., Mostafa A., Al-Karmalawy A.A. Design and synthesis of new 4-(2-nitrophenoxy) benzamide derivatives as potential antiviral agents: Molecular modeling and in vitro antiviral screening. New J. Chem. 2021;45:16557\u201316571. doi: 10.1039/D1NJ02710G.", "ArticleIdList": ["10.1039/D1NJ02710G"]}, {"Citation": "Park J.H., Liu Y., Lemmon M.A., Radhakrishnan R. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem. J. 2012;448:417\u2013423. doi: 10.1042/BJ20121513.", "ArticleIdList": ["10.1042/BJ20121513", "PMC3507260", "23101586"]}, {"Citation": "Sogabe S., Kawakita Y., Igaki S., Iwata H., Miki H., Cary D.R., Takagi T., Takagi S., Ohta Y., Ishikawa T. Structure-based approach for the discovery of pyrrolo [3, 2-d] pyrimidine-based EGFR T790M/L858R mutant inhibitors. ACS Med. Chem. Lett. 2012;4:201\u2013205. doi: 10.1021/ml300327z.", "ArticleIdList": ["10.1021/ml300327z", "PMC4027575", "24900643"]}, {"Citation": "Husein D.Z., Hassanien R., Khamis M. Cadmium oxide nanoparticles/graphene composite: Synthesis, theoretical insights into reactivity and adsorption study. RSC Adv. 2021;11:27027\u201327041. doi: 10.1039/D1RA04754J.", "ArticleIdList": ["10.1039/D1RA04754J", "PMC9037664", "35480026"]}, {"Citation": "Wang T., Husein D.Z. Novel synthesis of multicomponent porous nano-hybrid composite, theoretical investigation using DFT and dye adsorption applications: Disposing of waste with waste. Environ. Sci. Pollut. Res. 2022:1\u201328. doi: 10.1007/s11356-022-20050-2.", "ArticleIdList": ["10.1007/s11356-022-20050-2", "35460480"]}, {"Citation": "Illustrated Glossary of Organic Chemistry. Electrostatic Potential Map.  [(accessed on 20 August 2022)].  Available online:  http://www.chem.ucla.edu/~harding/IGOC/E/electrostatic_potential_map.html."}, {"Citation": "Norinder U., Bergstr\u00f6m C.A. Prediction of ADMET properties. ChemMedChem Chem. Enabling Drug Discov. 2006;1:920\u2013937. doi: 10.1002/cmdc.200600155.", "ArticleIdList": ["10.1002/cmdc.200600155", "16952133"]}, {"Citation": "Dearden J.C. In silico prediction of drug toxicity. J. Comput.-Aided Mol. Des. 2003;17:119\u2013127. doi: 10.1023/A:1025361621494.", "ArticleIdList": ["10.1023/A:1025361621494", "13677480"]}, {"Citation": "Idakwo G., Luttrell J., Chen M., Hong H., Zhou Z., Gong P., Zhang C. A review on machine learning methods for in silico toxicity prediction. J. Environ. Sci. Health Part C. 2018;36:169\u2013191. doi: 10.1080/10590501.2018.1537118.", "ArticleIdList": ["10.1080/10590501.2018.1537118", "30628866"]}, {"Citation": "Kruhlak N., Benz R., Zhou H., Colatsky T. (Q) SAR modeling and safety assessment in regulatory review. Clin. Pharmacol. Ther. 2012;91:529\u2013534. doi: 10.1038/clpt.2011.300.", "ArticleIdList": ["10.1038/clpt.2011.300", "22258468"]}, {"Citation": "Zygmunt M., Zmudzki P., Chlon-Rzepa G., Sapa J., Pawlowski M. Synthesis and Analgesic Activity of 3, 7-dimethylpurine-2, 6-dion-1-yl Derivatives of Acetic and Butanoic Acid. Lett. Drug Des. Discov. 2014;11:1204\u20131213. doi: 10.2174/1570180811666140718162449.", "ArticleIdList": ["10.2174/1570180811666140718162449"]}, {"Citation": "Elwan A., Abdallah A.E., Mahdy H.A., Dahab M.A., Taghour M.S., Elkaeed E.B., Mehany A.B., Nabeeh A., Adel M., Alsfouk A.A. Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation. Molecules. 2022;27:5047. doi: 10.3390/molecules27155047.", "ArticleIdList": ["10.3390/molecules27155047", "PMC9370530", "35956997"]}, {"Citation": "Nossier E.S., Alasfoury R.A., Hagras M., El-Manawaty M., Sayed S.M., Ibrahim I.M., Elkady H., Eissa I.H., Elzahabi H.S.A. Modified pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as EGFRWT and EGFRT790M inhibitors: Design, synthesis, and anti-cancer evaluation. J. Mol. Struct. 2022;1270:133971. doi: 10.1016/j.molstruc.2022.133971.", "ArticleIdList": ["10.1016/j.molstruc.2022.133971", "PMC9291687", "35821615"]}, {"Citation": "Alsaif N.A., Taghour M.S., Alanazi M.M., Obaidullah A.J., Al-Mehizia A.A., Alanazi M.M., Aldawas S., Elwan A., Elkady H. Discovery of new VEGFR-2 inhibitors based on bis ([1, 2, 4] triazolo)[4, 3-a: 3\u2019, 4\u2019-c] quinoxaline derivatives as anticancer agents and apoptosis inducers. J. Enzym. Inhib. Med. Chem. 2021;36:1093\u20131114. doi: 10.1080/14756366.2021.1915303.", "ArticleIdList": ["10.1080/14756366.2021.1915303", "PMC8168755", "34056992"]}, {"Citation": "Alanazi M.M., Eissa I.H., Alsaif N.A., Obaidullah A.J., Alanazi W.A., Alasmari A.F., Albassam H., Elkady H., Elwan A. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. J. Enzym. Inhib. Med. Chem. 2021;36:1760\u20131782. doi: 10.1080/14756366.2021.1956488.", "ArticleIdList": ["10.1080/14756366.2021.1956488", "PMC8344243", "34340610"]}, {"Citation": "Taghour M.S., Mahdy H.A., Gomaa M.H., Aglan A., Eldeib M.G., Elwan A., Dahab M.A., Elkaeed E.B., Alsfouk A.A., Khalifa M.M. Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and antiproliferative evaluation. J. Enzym. Inhib. Med. Chem. 2022;37:2063\u20132077. doi: 10.1080/14756366.2022.2103552.", "ArticleIdList": ["10.1080/14756366.2022.2103552", "PMC9327782", "35875937"]}, {"Citation": "Elkaeed E.B., Eissa I.H., Elkady H., Abdelalim A., Alqaisi A.M., Alsfouk A.A., Elwan A., Metwaly A.M. A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease. Int. J. Mol. Sci. 2022;23:8407. doi: 10.3390/ijms23158407.", "ArticleIdList": ["10.3390/ijms23158407", "PMC9369012", "35955547"]}, {"Citation": "Elkaeed E.B., Youssef F.S., Eissa I.H., Elkady H., Alsfouk A.A., Ashour M.L., El Hassab M.A., Abou-Seri S.M., Metwaly A.M. Multi-step in silico discovery of natural drugs against COVID-19 targeting main protease. Int. J. Mol. Sci. 2022;23:6912. doi: 10.3390/ijms23136912.", "ArticleIdList": ["10.3390/ijms23136912", "PMC9266348", "35805916"]}, {"Citation": "Elkaeed E.B., Yousef R.G., Elkady H., Gobaara I.M.M., Alsfouk B.A., Husein D.Z., Ibrahim I.M., Metwaly A.M., Eissa I.H. Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects. Molecules. 2022;27:4606. doi: 10.3390/molecules27144606.", "ArticleIdList": ["10.3390/molecules27144606", "PMC9317904", "35889478"]}, {"Citation": "Gaussian.  [(accessed on 1 July 2022)].  Available online:  https://gaussian.com/citation/"}, {"Citation": "Frisch M., Trucks G.W., Schlegel H.B., Scuseria G.E., Robb M.A., Cheeseman J.R., Scalmani G., Barone V., Mennucci B., Petersson G. Gaussian 09. Gaussian, Inc.; Wallingford, CT, USA: 2009. revision D. 01."}, {"Citation": "Taghour M.S., Elkady H., Eldehna W.M., El-Deeb N.M., Kenawy A.M., Elkaeed E.B., Alsfouk A.A., Alesawy M.S., Metwaly A.M., Eissa I.H. Design and synthesis of thiazolidine-2, 4-diones hybrids with 1, 2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: In-vitro anticancer evaluation and in-silico studies. J. Enzym. Inhib. Med. Chem. 2022;37:1903\u20131917. doi: 10.1080/14756366.2022.2085693.", "ArticleIdList": ["10.1080/14756366.2022.2085693", "PMC9272924", "35801403"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "7", "Day": "31"}, {"Year": "2022", "Month": "8", "Day": "28"}, {"Year": "2022", "Month": "9", "Day": "6"}, {"Year": "2022", "Month": "9", "Day": "23", "Hour": "1", "Minute": "36"}, {"Year": "2022", "Month": "9", "Day": "24", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "9", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "9", "Day": "9"}], "PublicationStatus": "epublish", "ArticleIdList": ["36144596", "PMC9500845", "10.3390/molecules27185859", "molecules27185859"]}}], "PubmedBookArticle": []}